c-Met-IN-22

• UNSPSC Description:

  c-Met-IN-22 (compound 51am) is an orally active inhibitor against c-Met with an IC50 value of 2.54 nM. c-Met-IN-22 has antiproliferative and antitumor activities. c-Met-IN-22 induces cell apoptosis[1].

• Target Antigen:

  Apoptosis; c-Met/HGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/c-met-in-22.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=NC(C2=CC=C(F)C(Cl)=C2)=CS1)NC3=CC=C(OC4=C(Cl)C(Cl)=NC=C4)C(F)=C3

• Molecular Weight:

  512.74

• References & Citations:

  [1]Xiang Nan,et al. Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment. J Enzyme Inhib Med Chem. 2023 Dec;38

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported